Eli Lilly & Co. plans to buy Merida Biosciences Inc. for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases. The move is part of an effort to build beyond the weight-loss and diabetes markets that made Lilly the largest pharmaceutical company in the world, according to a Bloomberg Real Estate summary.
Lilly has been on a record spending spree, having announced more than $20 billion in deals so far in 2026. The drugmaker has been using the windfall from its Zepbound and Mounjaro shots to diversify its pipeline, mainly targeting medicines in earlier stages as it seeks to position itself to develop the next blockbuster. The Merida transaction is described only as a planned cash acquisition, with no additional financing terms, closing conditions, or target-specific product details provided in the available summary.
The supported implication is that Lilly is deliberately redirecting capital from its highly successful incretin franchise into adjacent therapeutic areas, particularly autoimmune and allergic diseases, to reduce concentration risk and build a broader late-stage pipeline. The reported deal value of up to $2.88 billion in cash indicates a sizable but not transformational commitment relative to Lilly's overall 2026 deal activity, which already exceeds $20 billion.
What remains unknown is whether the Merida acquisition includes milestone-based contingent payments, what specific autoimmune or allergy assets Merida holds, and how advanced those programs are. The evidence level is a single summary, so no independent confirmation of the deal structure, regulatory hurdles, or expected closing timeline is available. The source is a secondary Bloomberg Real Estate video summary, and the underlying article retrieval was blocked.